Article Details
Retrieved on: 2021-01-29 09:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
JAK inhibitor Xeljanz is one of Pfizer's top-selling drugs, despite a 'black box' warning for blood clots and cancers added to its label in 2019. Now ...
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here